Molecular Predictors of Sensitivity to the MET Inhibitor PHA665752 in Lung Carcinoma Cells Daisuke Matsubara, MD, PhD, Shumpei Ishikawa, MD, PhD, Sachiko.

Slides:

Advertisements

Similar presentations

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Advertisements

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma Maria I. Toki, MD,

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

RET Mutation and Expression in Small-Cell Lung Cancer

TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Identifying Inhibitors of Epithelial-Mesenchymal Transition by Connectivity Map–Based Systems Approach Ajaya Kumar Reka, PhD, Rork Kuick, MS, Himabindu.

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation Hiroko Endo, BPHRM, Jiro Okami, MD, PhD, Hiroaki Okuyama, MD,

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer Hiroyuki.

Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC- 2/ad Daisuke Matsubara, MD, PhD, Yoshihiko Kanai, Shumpei Ishikawa,

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

Interleukin-22 Is Frequently Expressed in Small- and Large-Cell Lung Cancer and Promotes Growth in Chemotherapy-Resistant Cancer Cells Sebastian Kobold,

Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression Toran Sanli,

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer Seiichi Ikeda, MSc, Tatsuro Okamoto, MD,

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine.

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation Hiroko Endo, BPHRM, Jiro Okami, MD, PhD, Hiroaki Okuyama, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Volume 10, Issue 1, Pages (July 2006)

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer Edward.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer Kelsie L. Thu,

V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors Satsuki Matsushima, BSc, Kouki Ohtsuka,

Erratum Journal of Thoracic Oncology

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation Junya Nakade,

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Mitotic Inhibitors Journal of Thoracic Oncology

Aberrant Regulation of the MRP3 Gene in Non-small Cell Lung Carcinoma

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

Ly6/uPAR-Related Protein C4

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Marijn T.M. van Jaarsveld, Difan Deng, Erik A.C. Wiemer, Zhike Zi

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

Tivantinib does not inhibit MET function.

Presentation transcript:

Molecular Predictors of Sensitivity to the MET Inhibitor PHA665752 in Lung Carcinoma Cells Daisuke Matsubara, MD, PhD, Shumpei Ishikawa, MD, PhD, Sachiko Oguni, Hiroyuki Aburatani, MD, PhD, Masashi Fukayama, MD, PhD, Toshiro Niki, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 9, Pages 1317-1324 (September 2010) DOI: 10.1097/JTO.0b013e3181e2a409 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Sensitivity of 41 non-small cell lung cancer cell lines to PHA665752 and their genetic statuses. Left panel shows cell line names, histologies, sources, sensitivities, and the values of IC50. Middle panel shows the viability of cells with each PHA665752 concentration in a different color. Right panel shows the genetic statuses of 41 cell lines. Details are shown at the bottom of the figure. L27 was described in a previous study.11 Journal of Thoracic Oncology 2010 5, 1317-1324DOI: (10.1097/JTO.0b013e3181e2a409) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Dose-response curves of representative cell lines of each group: H1648 (sensitive), PC14 (intermediate), and LC-2/ad (resistant). The x axis indicates the log10(concentration of PHA665752) and the y axis indicates the %cell viability = (mean absorbance in test wells)/(mean absorbance in control well) × 100. Journal of Thoracic Oncology 2010 5, 1317-1324DOI: (10.1097/JTO.0b013e3181e2a409) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Expressions of MET and phospho-MET and their relationships with sensitivities to the MET inhibitor. The expressions of MET and phospho-MET were determined by Western blot analysis. The results were corrected for beta-actin and expressed in arbitrary units. A, Expression of MET in 41 cell lines. The protein expression of MET was consistent with the mRNA expression of MET determined by oligonucleotide array analysis (not shown). Cell lines were arranged in ascending order of their IC50 values. MET was strongly expressed in 16 cell lines (MET/beta-actin >2.0, red bars). B, Expression of phospho-MET in 41 cell lines. Phospho-MET was strongly expressed in 13 cell lines (p-MET/beta-actin >2.0, red bars). C and D, Box and whisker plots of MET (C) and phospho-MET (D) expression levels in the sensitive, intermediate, and resistant groups. E, Correlation between MET and phospho-MET expression in 41 cell lines. The results are shown in a two-way scatter plot in which the x axis indicates the expression of MET corrected for beta-actin and the y axis indicates the expression of phospho-MET corrected for beta-actin. Purple, orange, and light blue rhombuses indicate “sensitive,” “intermediate,” and “resistant” cell lines, respectively. Cell lines harboring MET amplification are surrounded by black circles. F and G, Expressions of MET (F) and phospho-MET (G) in 11 KRAS-mutated cell lines. Cell lines were arranged in ascending order of their IC50 values. Journal of Thoracic Oncology 2010 5, 1317-1324DOI: (10.1097/JTO.0b013e3181e2a409) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 The effects of PHA665752 on the phosphorylation levels of MET, ERK, and AKT. Nine cell lines with high phospho-MET expression consisted of three sensitive cell lines (EBC1, H1993, and H1648), five resistant cell lines (HCC8227, H1975, LC-2/ad, Calu3, and H441), and one intermediate cell line (H2009). MET dephosphorylation was seen in all the cell lines tested. Dephosphorylation of ERK and AKT were seen in three of the three MET-amplified cell lines (EBC1, H1993, and H1648) and one of the two KRAS-mutant cell lines (“resistant” H441) but not in the four resistant cell lines (HCC8227, H1975, LC-2/ad, and Calu3). Journal of Thoracic Oncology 2010 5, 1317-1324DOI: (10.1097/JTO.0b013e3181e2a409) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Expressions of E-cadherin and vimentin and their relationships with sensitivities to the MET inhibitor. A and B, Box and whisker plots showing the distribution of E-cadherin (A) and vimentin (B) gene expression levels in the sensitive, intermediate, and resistant groups. C and D, Expressions of E-cadherin (C) and vimentin (D), their relationships to the genetic statuses of MET, EGFR, HER2, and KRAS, and their sensitivities to the MET inhibitor. White bars, brown bars, and black bars indicate sensitive, intermediate, and resistant cell lines, respectively. Cell lines were arranged according to their genetic abnormalities as shown in the lower panel. METamp, MET amplification; EGFRmut, EGFR mutation; METmut, MET mutation; HER2amp, HER2 amplification; HER2mut, HER2 mutation; KRASmut, KRAS mutation. Journal of Thoracic Oncology 2010 5, 1317-1324DOI: (10.1097/JTO.0b013e3181e2a409) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions